Can a triple therapy shrink head and neck tumors before surgery?

NCT ID NCT07732634

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a new drug called RiMO-301, given alongside radiation and the immunotherapy pembrolizumab (Keytruda), can shrink tumors before surgery in people with resectable, locally advanced head and neck cancer. The study will measure how many patients' tumors respond to this pre-surgery treatment and track survival for up to two years. About 20 participants will receive the combination therapy before undergoing surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of an experimental drug called RiMO-301, radiation therapy, and the immunotherapy drug pembrolizumab (Keytruda)
What this could lead to
If successful, this approach could shrink tumors before surgery, potentially improving outcomes for people with locally advanced head and neck cancer.
What could go wrong
This is a small, early-phase trial, so results may not apply to all patients. The combination therapy may cause side effects, and it is not yet known if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Illinois at Chicago

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.